New supplement aims to rebuild knee cartilage – early trial underway

NCT ID NCT07323745

Recruiting now Disease control Sponsor: Universiti Sains Malaysia Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether Mobithron Advance, a daily oral supplement made from undenatured type II collagen, can slow or reverse cartilage loss in people with knee osteoarthritis. Over 12 months, 84 participants will take either the supplement or a placebo. Researchers will use MRI scans to measure cartilage thickness and track pain scores, aiming to see if the drug can modify the disease rather than just ease symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: undenatured type II collagen (UC-II) oral tablets
What this could lead to: If it works, this could point toward a treatment that slows or reverses cartilage loss in knee osteoarthritis, potentially reducing pain and delaying the need for surgery.
What could go wrong: This is a very early (Phase 1) trial with only 84 people, so results may not be conclusive. The supplement may not work better than placebo, and long-term safety is still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOARTHRITIS (OA) OF THE KNEE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteoarthritis osteoarthritis, knee

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OSTEOARTHRITIS (OA) OF THE KNEE

Contacts and locations

Locations

Hospital Univerisiti Sains Malaysia (HUSM)
RECRUITING

Kota Bharu, Kelantan, 16150, Malaysia

More trials for these conditions

Other studies related to the condition(s) this trial covers.